{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:30:57Z","timestamp":1790656257993,"version":"4.1.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are rare, life-threatening immunologic reactions. Previous relevant literature has provided limited information regarding this disease\u2019s genetic susceptibility and management principles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed to describe a phenobarbital-induced TEN case report with <jats:italic>HLA-B*15:02<\/jats:italic> and <jats:italic>HLA-B*58:01<\/jats:italic> negative, <jats:italic>CYP2C19*1\/*2<\/jats:italic>. In addition, we revised the existing literature on phenobarbital-induced SJS\/TEN to explore its clinical characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We describe a woman undergoing treatment with Phenobarbital for status epilepticus who developed classic cutaneous findings of TEN. A systematic search was conducted in the PubMed, Medline, WanFang, and CNKI databases from 1995 to 2023. The search terms used were \u201cStevens-Johnson Syndrome,\u201d \u201cToxic Epidermal Necrolysis,\u201d and \u201cPhenobarbital.\u201d<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We report a case of TEN resulting from phenobarbital; it tested negative for the <jats:italic>HLA-B*15:02<\/jats:italic> and <jats:italic>HLA-B*58:01<\/jats:italic> allele and <jats:italic>CYP2C19*1<\/jats:italic>\/<jats:italic>*2<\/jats:italic> intermediate metabolism. Supportive treatment with steroids and antihistamines resulted in complete resolution of the skin lesions and improvement in clinical symptoms after 14\u00a0days. Physicians and clinical pharmacists should be aware of these potential phenobarbital-related adverse events and closely monitor patients with first-time use of phenobarbital. Among 19 cases were identified in the literature, with 11 (57.9%) cases of SJS, 6 (31.6%) cases of TEN, and 2 (7.2%) cases of SJS-TEN\/DRESS overlap. A total of 5 (26.3%) did not survive, of which 4 (21.1%) were under 12\u00a0years old and 1 (5.3%) was over 12\u00a0years old.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Phenobarbital-induced SJS\/TEN may still occur in patients who test negative for <jats:italic>HLA-B*15:02<\/jats:italic> and <jats:italic>HLA-B*58:01, CYP2C19*1<\/jats:italic>\/<jats:italic>*2<\/jats:italic>. Most cutaneous adverse events occur early in the course of Phenobarbital therapy and should be closely monitored early in the course of treatment. In addition, Phenobarbital should be used with caution in patients with a history of asthma and allergy to antipyretics and analgesics.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1433506","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:19:04Z","timestamp":1722489544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Toxic epidermal necrolysis caused by phenobarbital: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Jie","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XueYan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8163588","DOI":"10.1155\/2022\/8163588","article-title":"Clinical and epidemiological features of patients with drug-induced stevens-johnson syndrome and toxic epidermal necrolysis in Iran: different points of children from adults","volume":"2022","author":"Abtahi-Naeini","year":"2022","journal-title":"Int. J. Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.18502\/ijaai.v23i2.15320","article-title":"Antiepileptic medication-induced severe cutaneous adverse reactions in hospitalized children: a retrospective study","volume":"23","author":"Abtahi-Naeini","year":"2024","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4103\/0253-7613.99344","article-title":"Phenobarbital induced Stevens-Johnson syndrome in a child","volume":"44","author":"Agnihotri","year":"2012","journal-title":"Indian J. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD010891","DOI":"10.1002\/14651858.CD010891.pub2","article-title":"Genetic testing for prevention of severe drug\u2010induced skin rash","volume":"7","author":"Alfirevic","year":"2019","journal-title":"Cochrane db. Syst. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13223-021-00589-4","article-title":"Toxic epidermal necrosis associated with phenobarbitone: a case report and brief review of the literatures","volume":"17","author":"Ayele","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/epi.14591","article-title":"Stevens\u2010Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and drug administration adverse event reporting system","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9343(88)90054-X","article-title":"Pharmacologic interactions between valproate and other drugs","volume":"84","author":"Bourgeois","year":"1988","journal-title":"Am. J. Med."},{"key":"B8","article-title":"Impact of CYP2C9 and CYP2C19 gene polymorphisms on drug metabolism and advances in individualized dosing research","author":"Chen","year":"2014","journal-title":"China Drug Appl. Monit."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1226333","DOI":"10.3389\/fphar.2023.1226333","article-title":"The participation of clinical pharmacists in the treatment of patients with central nervous system infection can improve the effectiveness and appropriateness of anti-infective treatments: a retrospective cohort study","volume":"14","author":"Cheng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.12809\/hkmj2210131","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Hong Kong","volume":"30","author":"Cheung","year":"2024","journal-title":"Hong Kong Med. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0190-9622(99)70508-6","article-title":"Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital","volume":"40","author":"Duncan","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Fouchard","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/FTD.0b013e318030def0","article-title":"Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese","volume":"29","author":"Goto","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"B17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","article-title":"Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States","volume":"76","author":"Hsu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of stevens-johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1007-6611.2001.06.052","article-title":"A case of Stevens-Johnson syndrome due to therapeutic amount of luminal","volume":"486","author":"Hu","year":"2001","journal-title":"J. Shanxi Med. Univ."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jfma.2021.09.025","article-title":"Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results","volume":"121","author":"Huang","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3969\/j.issn.1672-3384.2018.09.018","article-title":"A case study of Steve Johnson syndrome\/toxic epidermal necrolysis induced by antiepileptic drugs","volume":"16","author":"Jing","year":"2018","journal-title":"J. Clin. Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.11604\/pamj.2014.17.202.3385","article-title":"Toxic epidermal necrolysis induced by phenobarbital in a Rwandan child: report of a case","volume":"17","author":"Kaputu-Kalala-Malu","year":"2014","journal-title":"Pan Afr. Med. J."},{"key":"B25","article-title":"Stevens johnson syndrome secondary to phenobarbitone","author":"Kheir","year":"2012","journal-title":"Khartoum Med. juornal."},{"key":"B26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/archdischild-2011-300538","article-title":"Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures","volume":"97","author":"Lee","year":"2012","journal-title":"Arch. Dis. Child."},{"key":"B27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin. Rev. Allerg. Immu."},{"key":"B28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.13748\/j.cnki.issn1007-7693.2013.01.016","article-title":"A case of Stevens-Johnson syndrome induced by intramuscular injection of sodium phenobarbital","volume":"30","author":"Li","year":"2013","journal-title":"Mod. Appl. Pharm. China"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/pai.12058","article-title":"Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children","volume":"24","author":"Manuyakorn","year":"2013","journal-title":"Pediatr. Allergy Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bjd.17841","article-title":"British Association of Dermatologists guidelines for the management of StevensJohnson syndrome\/toxic epidermal necrolysis in children and young people 2018","volume":"181","author":"McPherson","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2004","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.clindermatol.2020.06.016","article-title":"Diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"38","author":"Noe","year":"2020","journal-title":"Clin. Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"","journal-title":"BMJ"},{"key":"B38","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.19845\/j.cnki.zfysjjbzz.2011.09.002","article-title":"Correlation between CYP2C9 and CYP2C19 gene polymorphisms and phenobarbital blood levels in Hui and Han Chinese patients with epilepsy","author":"Qi","year":"2011","journal-title":"J. Stroke Neurol. Dis."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3321\/j.issn:1001-5213.2005.05.060","article-title":"A case of paediatric death due to toxic epidermal necrolysis with loosening of the skin caused by phenobarbital","volume":"483","author":"Qiu","year":"2005","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B41","doi-asserted-by":"publisher","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification","volume":"102","author":"Roujeau","year":"1994","journal-title":"J. Invest. Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.burns.2015.03.012","article-title":"Complications of Stevens-Johnson syndrome beyond the eye and skin","volume":"42","author":"Saeed","year":"2016","journal-title":"Burns"},{"key":"B43","doi-asserted-by":"publisher","first-page":"187.e1","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J. Am. Acad. Dermatology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2040622319894469","DOI":"10.1177\/2040622319894469","article-title":"Multidisciplinary care in Stevens-Johnson syndrome","volume":"11","author":"Shanbhag","year":"2020","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e19431","DOI":"10.1097\/MD.0000000000019431","article-title":"Fatal pediatric Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: three case reports","volume":"99","author":"Shi","year":"2020","journal-title":"Med. Baltim."},{"key":"B46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.seizure.2021.07.011","article-title":"Severe cutaneous adverse reactions in Asians: trends observed in culprit anti-seizure medicines using VigiBase\u00ae","volume":"91","author":"Shukla","year":"2021","journal-title":"Seizure"},{"key":"B47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.18203\/2319-2003.ijbcp20222753","article-title":"A case of phenobarbitone induced Stevens-Johnson syndrome-toxic epidermal necrolysis along with its causality assessment","volume":"11","author":"Singh","year":"2022","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11596-014-1247-7","article-title":"Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China","volume":"34","author":"Sun","year":"2014","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.yebeh.2018.10.014","article-title":"Blood concentration, efficacy, and adverse events of phenobarbital: a prospective study in rural China","volume":"90","author":"Sun","year":"2019","journal-title":"Epilepsy Behav."},{"key":"B50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/0976-0105.195130","article-title":"Antiepileptic drugs-induced stevens-johnson syndrome: a case series","volume":"8","author":"Trivedi","year":"2017","journal-title":"J. Basic Clin. Pharm."},{"key":"B51","article-title":"Epidermal necrolysis (Stevens\u2013Johnson syndrome and toxic epidermal necrolysis)","volume-title":"Fitzpatrick\u2019s Dermatology in General Medicine, 8e","author":"Valeyrie-Allanore","year":"2012"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2333794X231216556","DOI":"10.1177\/2333794X231216556","article-title":"Overlapping stevens-johnson syndrome and DRESS syndrome caused by phenobarbital: a Vietnamese case report","volume":"10","author":"Van Nguyen","year":"2023","journal-title":"Glob. Pediatr. Health"},{"key":"B53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3321\/j.issn:1003-3734.2006.03.020","article-title":"A case of toxic epidermal necrolytic-relaxative drug rash caused by phenobarbital scopolamine","author":"Wei","year":"2006","journal-title":"Chin. J. New Drugs"},{"key":"B54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1212\/WNL.0b013e31823b478c","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs in Asians","volume":"77","author":"Yang","year":"2011","journal-title":"Neurology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/epi.12026","article-title":"How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years","volume":"53","author":"Yasiry","year":"2012","journal-title":"Epilepsia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2710.2006.00712.x","article-title":"Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach","volume":"31","author":"Yukawa","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"200","DOI":"10.17511\/ijmrr.2018.i03.12","article-title":"A case report on phenobarbitone induced stevens-johnson syndrome: an alarming hypersensitivity reaction","volume":"6","author":"Zankat","year":"2018","journal-title":"Int. J. Med. Res. Rev."},{"key":"B59","article-title":"A case of toxic epidermal necrolysis with loosening of the epidermis caused by phenobarbital","volume":"305","author":"Zhang","year":"1995","journal-title":"J. Bengbu Med. Coll."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3870\/j.issn.1004-0781.2003.07.046","article-title":"Steven-Johnson syndrome induced by phenobarbital","volume":"492","author":"Zhou","year":"2003","journal-title":"Med. Her."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1433506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:19:19Z","timestamp":1722489559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1433506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":60,"alternative-id":["10.3389\/fphar.2024.1433506"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1433506","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"article-number":"1433506"}}